Globus Medical's Q4 Earnings Beat Estimates, But FY22 Outlook Lags

Globus Medical Inc's GMED Q4 sales reached $250 million, +7.1% Y/Y (up 7.4% on a constant currency basis), beating the consensus of $243.52 million.

• The U.S. net sales, including robotics, increased by 7.2% to $212.96 million. International net sales increased by 6.8% and 8.7% on a constant currency basis, to $37.06 million.
• Sales from Musculoskeletal Solutions increased 4.30% to $224.62 million.
• The adjusted EPS of $0.49 surpassed the consensus of $0.47.
• Non-GAAP adjusted EBITDA was $85.2 million, or 34.1% of net sales.
• "The clinical superiority of ExcelsiusGPS continues to be the primary factor driving Enabling Technology momentum, which produced a record $25 million in revenue for the fourth quarter and $81 million for 2021, a 100% increase over 2020. Musculoskeletal Solutions also completed another outstanding year of market-share gains, led by US Spine with 18% growth, International Spine with 12% growth and Trauma with 39% growth," commented Dave Demski, President & CEO.
• Guidance: Globus Medical expects net sales of $1.025 billion, compared to the estimate of $1.05 billion.
• The Company forecasts an adjusted EPS of $2.10, lower than the consensus of $2.26.
• Price Action: GMED shares closed 2.97% lower at $66.34 on Thursday.